AU2022262593A1 - Pharmaceutical composition comprising the compound smtp-7 - Google Patents

Pharmaceutical composition comprising the compound smtp-7 Download PDF

Info

Publication number
AU2022262593A1
AU2022262593A1 AU2022262593A AU2022262593A AU2022262593A1 AU 2022262593 A1 AU2022262593 A1 AU 2022262593A1 AU 2022262593 A AU2022262593 A AU 2022262593A AU 2022262593 A AU2022262593 A AU 2022262593A AU 2022262593 A1 AU2022262593 A1 AU 2022262593A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
additive
smtp
composition according
amphipathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022262593A
Other languages
English (en)
Inventor
Keiko Hasegawa
Keiji Hasumi
Naoko Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corxel Pharmaceuticals Hong Kong Ltd
Original Assignee
Corxel Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corxel Pharmaceuticals Hong Kong Ltd filed Critical Corxel Pharmaceuticals Hong Kong Ltd
Publication of AU2022262593A1 publication Critical patent/AU2022262593A1/en
Assigned to JI XING PHARMACEUTICALS HONG KONG LIMITED reassignment JI XING PHARMACEUTICALS HONG KONG LIMITED Request for Assignment Assignors: BIOGEN MA INC.
Assigned to CORXEL PHARMACEUTICALS HONG KONG LIMITED reassignment CORXEL PHARMACEUTICALS HONG KONG LIMITED Amend patent request/document other than specification (104) Assignors: JI XING PHARMACEUTICALS HONG KONG LIMITED
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2022262593A 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7 Pending AU2022262593A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021070892 2021-04-20
JP2021070892 2021-04-20
PCT/US2022/025462 WO2022226013A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Publications (1)

Publication Number Publication Date
AU2022262593A1 true AU2022262593A1 (en) 2023-11-02

Family

ID=81648879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022262593A Pending AU2022262593A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Country Status (9)

Country Link
US (1) US20240238252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525239A (cg-RX-API-DMAC7.html)
KR (1) KR20230173129A (cg-RX-API-DMAC7.html)
CN (1) CN117279634A (cg-RX-API-DMAC7.html)
AU (1) AU2022262593A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021803A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214630A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JPWO2007040082A1 (ja) 2005-10-06 2009-04-16 国立大学法人東京農工大学 腎炎治療又は予防用医薬組成物及びその製造方法
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP2008201688A (ja) * 2007-02-16 2008-09-04 Tms Co Ltd 皮膚老化防止剤、化粧料及び皮膚外用剤
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
WO2011125930A1 (ja) 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Smtp一群又はsmtp-7の製造中間体及びその化学的製造方法
US20240238248A1 (en) * 2021-05-10 2024-07-18 Ji Xing Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Also Published As

Publication number Publication date
KR20230173129A (ko) 2023-12-26
WO2022226013A1 (en) 2022-10-27
JP2024525239A (ja) 2024-07-11
CA3214630A1 (en) 2022-10-27
CN117279634A (zh) 2023-12-22
BR112023021803A2 (pt) 2024-01-23
US20240238252A1 (en) 2024-07-18
EP4326258A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
AU2022202629B2 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
KR20160135372A (ko) 리셉터 티로신 키나제 저해(RTKi) 화합물을 눈에 전달하기 위한 약학 조성물
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
AU2021233206A1 (en) Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
WO2016171152A1 (ja) 角膜障害の治療剤、改善剤または予防剤
EP4495122A1 (en) Artemisinin derivatives, preparation method therefor, and uses thereof
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
EP2620153A1 (en) 5 alpha-androstane (alkyl)-3 beta,5,6 beta-triol injection and preparation method therefor
JP3502574B2 (ja) 眼感染症治療用眼軟膏剤
WO2015175954A1 (en) Alpha v integrin antagonist compositions
KR101891078B1 (ko) 황반변성 예방 또는 치료용 약학 조성물
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
US20200345637A1 (en) Suspension compositions of multi-target inhibitors
US20240024299A1 (en) Use of drugs that stiffen mature gametocytes for blocking transmission of plasmodium parasites
EP1884236B1 (en) Angiogenesis inhibitor containing amine derivative as active ingredient
EP4415720A1 (en) Novel parenteral composition comprising linagliptin or its salts
HK40100601A (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
HK40000009A (zh) 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
EA043008B1 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JI XING PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER APPLICANT(S): BIOGEN MA INC.

HB Alteration of name in register

Owner name: CORXEL PHARMACEUTICALS HONG KONG LIMITED

Free format text: FORMER NAME(S): JI XING PHARMACEUTICALS HONG KONG LIMITED